Incorporating biomarker-driven patient stratification (e.g., PD-L1 status, tumor-infiltrating lymphocytes, and BRCA mutation) and evaluating the effects of host factors such as age, microbiome, and comorbidities will be critical to optimizing outcomes. The gene discussed is CD274; the disease is neoplasm.